Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$0.69
-$0.03(-3.63%)
At close: 4:00 PM EDT
$0.69
-$0.03(-3.63%)
Day’s Range― - ―
52-Week Range$0.32 - $3.05
Previous CloseN/A
Volume381.42K
Average Volume (3M)399.98K
Market Cap
$23.82M
Enterprise Value$4.62
Total Cash (Recent Filing)$7.31M
Total Debt (Recent Filing)$270.00K
Price to Earnings (P/E)―
Beta2.79
Next Earnings
Nov 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding33,274,563
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside1494.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Funding RunwayThe $132 million financing materially extends liquidity and supports multiple clinical milestones through the second half of 2028, reducing near-term funding pressure while allowing management to advance the combined pipeline.
Expanded Clinical PipelineThe Kira acquisition adds complementary immune and rare-disease programs at different development stages, increasing potential sources of future value and reducing reliance on a single clinical asset.
Non-Dilutive Asset MonetizationThe licensing transaction provides upfront capital and potential downstream payments without requiring Jasper to fund all development internally, while external advancement can preserve value from the C5a-targeting assets.
Bears Say
Pre-Revenue Business ModelJasper remains dependent on clinical progress rather than commercial sales, leaving no operating revenue base to absorb research costs. Substantial losses indicate that profitability and operating leverage remain dependent on successful future approvals.
Persistent Cash BurnSustained negative operating and free cash flow means the company must continue relying on financing, partnerships, or asset monetization to fund development. This creates ongoing liquidity and execution risk even after the recent capital raise.
Listing Compliance RiskFailure to restore compliance could lead to further remedial actions, including a reverse split or potential delisting. Such outcomes can complicate financing, reduce market access, and distract management from clinical execution.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.32 and its highest was $3.05 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $23.82M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.168.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 33,274,563 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went down -8.459%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$11.00
▲(1494.20% Upside)
Technical Analysis
Ownership Overview
1.03% Insiders
4.31% Mutual Funds
25.00% Other Institutional Investors
66.21% Public Companies and
Individual Investors